In agreement with these results, projection of the GPS2KO and Myr-AKT gene signatures onto TCGA breast cancer survival curves revealed a marginal survival advantage associated with tumors with higher GPS2 expression/lower AKT activation (Figure 5G). Here, GPS2 is linked to breast cancer.